Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Anglo American's Sakatti copper project given 'strategic' status by EU

(Sharecast News) - Anglo American said on Tuesday that its Sakatti copper and polymetallic project in Finland has been designated as a 'strategic project' by the European Commission. Under the European Union's Critical Raw Materials Act (CRMA), 'strategic projects' are considered to be in the public interest due to their importance in ensuring security of supply of strategic raw materials in the EU, thereby benefiting from more efficient processing of permitting applications and therefore more predictable development timelines.

Alison Atkinson, Anglo's Projects & Development director, said: "We are delighted to be awarded Strategic Project status for Sakatti - an important milestone for this exceptional mineral deposit with a high concentration of future-enabling metals, including a primary product of copper, very much aligned with Finland's and the EU's critical raw materials priorities.

"The EU currently produces about 4% of the critical minerals it needs and has a stated ambition to increase this to 10%. With Sakatti expected to deliver around 100,000 tonnes of copper equivalent metal production per year from the early 2030s, we expect to play a significant role in helping to build Europe's capacity and secure the responsible supply of the metals and minerals required for decarbonising our energy and transport systems, numerous advanced technologies, and meeting the fast-growing demands of hundreds of millions of people in their everyday lives."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.